Aug 2026· Seizure· Vol 142, pp.
204-211
· 0 citations· 21 references
Medicine
TL;DR
WEE shows a recognizable electroclinical and neuroimaging profile with early drug-resistant epilepsy and profound developmental delay, which may facilitate early diagnosis and targeted genetic testing, particularly in populations with recurrent variants.
Abstract
Purpose
WWOX-related developmental and epileptic encephalopathy (WOREE) is a rare autosomal recessive disorder caused by biallelic pathogenic WWOX variants, characterized by very early-onset epilepsy, profound developmental delay, and progressive brain abnormalities. Detailed electroclinical descriptions remain limited.
Methods
We conducted a retrospective study of seven patients with pathogenic/likely pathogenic WWOX variants. Clinical features, seizure evolution, EEG findings, brain MRI, and genetic data were reviewed. Epilepsy syndromes were classified according to International League against Epilepsy (ILAE) criteria. Variants were identified through next-generation sequencing and interpreted following American College of Medical Genetics and Genomics (ACMG) guidelines.
Results
Median seizure onset was 3 months (range 2-6). Five patients presented with focal seizures evolving to infantile epileptic spasms syndrome (IESS), while two had IESS at onset. Epilepsy was drug-resistant in all. Developmental delay was evident from birth with generalized hypotonia, acquired microcephaly, and impaired visual attention. Four patients had dysmorphic features. During the IESS period, EEG showed hypsarrhythmia in six patients and a severely disorganized encephalopathic background that did not strictly fulfill the criteria for hypsarrhythmia in one. Brain MRI revealed abnormalities in all patients, including frontotemporal atrophy and corpus callosum hypoplasia; delayed myelination was observed in one case. Eight pathogenic/likely pathogenic WWOX variants were found; including one novel variant (NM_016373.4:c.571C>T, p.(Gln191*)). The recurrent splice-site variant NM_016373.4:c.107+1G>A was identified in five patients, suggesting a possible regional founder effect.
Conclusion
WOREE shows a recognizable electroclinical and neuroimaging profile with early drug-resistant epilepsy and profound developmental delay. Recognition of this pattern may facilitate early diagnosis and targeted genetic testing, particularly in populations with recurrent variants.
The findings suggest a potential increased frequency of seizures in classic infantile Pompe disease in comparison with unaffected children, occurring predominantly after the age of 7, and that epilepsy is part of the CNS phenotype.
M. C. Faraguna, Alexander Broomfield, S. Gasperini et al.· Neurology: Genetics· 0 citations
Introduction: Drug-resistant epilepsy affects approximately 25% of patients with epilepsy and requires complex, multidisciplinary therapeutic approaches. When associated with neuropsychiatric comorbidities and rare genetic syndromes, such as Bardet–Biedl syndrome (BBS), a primary ciliopathy, diagnostic and therapeutic...
Eliane Batista Silva, Cezar Filho dos Santos Liberal, Gabriella Cláudia Figueiredo Melo et al.· Acta neurológica colombiana· 0 citations
SLC33A1 mutation (Huppke-Brendel Syndrome) is a rare, autosomal recessive disorder associated with copper metabolism and characterized by global developmental delay, sensorineural hearing loss, congenital cataract and generalized hypotonia. We report two siblings under 6 years with novel SLC33A1 gene mutation, born fro...
OBJECTIVE
To characterize the epileptic spectrum associated with COQ4 variants through three newly identified patients and literature review.
METHODS
We retrospectively collected clinical data from three patients with COQ4 variants diagnosed at Chang Gung Memorial Hospital, Linkou Branch, between November 2021 and De...
Ju-Yin Hou, I-Jun Chou, Cheng-Yen Kuo et al.· Seizure· 0 citations
CNB was associated with sustained effectiveness and acceptable tolerability across pediatric DEEs and slow weight-based titration and proactive simplification of sodium channel blockers and clobazam may optimize benefit-risk.
Á. Aledo-Serrano, Adrián Valls-Carbó, E. González-Alguacil et al.· Epilepsia· 0 citations
Background and Objectives SLC6A1-related neurodevelopmental disorder (SLC6A1-NDD) is emerging as a leading genetic cause of epilepsy, autism spectrum disorder (ASD), and NDD caused by monoallelic loss of function variants in SLC6A1 (solute carrier family 6 member 1) which encodes a gamma-aminobutyric acid (GABA) transp...
Marie E. Varnet, Hamza Dahshi, Kimberly Goodspeed et al.· Neurology: Genetics· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.